Meibai Biopharma Secures Tens of Millions in Series A Funding, Ushering in Regenerative Medicine 2.0 Era
VCBeat (WeChat: vcbeat) learned at the earliest opportunity that on August 16,Meibo Biopharma (hereinafter referred to as “Meibo Bio”) announced the completion of its tens-of-millions-yuan Series A financing round. The round was led by Yahui Investment, with continued participation from Tengyun Big Health and existing shareholder Danlu Capital. Xinghan Capital served as the exclusive financial advisor.
Meibo Bio is the first enterprise in China to leverage in vitro tissue engineering technology for the efficient production of human-derived ECM composite collagen, and has currently achieved large-scale mass production.Upon completion of this round of financing, Meibo Biologics will accelerate the clinical validation of its fully human-derived collagen injection products, while continuing to increase R&D investment and refine its product portfolio.
Co-Founder and Chairman of Meibo BiotechXiao EDr. stated, “Since completing the angel financing round, the company has made significant progress in its production workshops, team building, and innovative technology platforms. The funds from this financing round will be primarily used for the construction of Phase II raw material production workshops and the submission of applications for several Class III medical device registrations. This will further strengthen and enhance our comprehensive R&D capabilities, while expanding and broadening our pipeline of innovative products. We are deeply grateful for the trust placed in us by our new shareholders and the continued support from our existing shareholders. We believe that, with our collective efforts, Meibo, driven by scientific innovation and grounded in high-quality manufacturing, will continue to advance into both the medical sector and the consumer market, building on its foundation in medical aesthetics, by mass-producing human-derived ECM-complexed collagen through in vitro tissue engineering.”
Lead InvestorYahui Investmentis a specialized fund focused on the frontiers of life sciences. Adhering to rigorous research in life sciences and a profound understanding of capital markets, Yahui Investment has invested in more than 30 companies since 2016, nurturing leading enterprises across multiple niche sectors. We have participated in and witnessed the vigorous development of China’s life sciences industry, contributing our modest efforts with great pride. Investment Director at Yahui InvestmentLin Sibostated: “We are focused on the extension of cutting-edge life science technologies into the medical aesthetics market, and we are highly optimistic about the company’s potential to become a leader in regenerative medical aesthetics by delivering revolutionary innovative products, leveraging its novel life science technologies and rigorous clinical practice experience.”
The co-investors in this round are also the angel-round investors.Danlu CapitalA leading healthcare-focused fund in China specializing in innovative medical technologies, co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner at Fenxiang Investment Management. The core team members all hail from prominent venture capital firms and possess extensive healthcare industry resources across China and the United States. Project LeadFang WenhanDanlu expressed its firm optimism about the upstream medical aesthetics market and the field of regenerative medicine. The company’s in vitro tissue engineering technology maximally restores the composition of human extracellular matrix complex collagen, which is expected to rapidly penetrate the medical aesthetics market with this product. Danlu will continue to support the company’s development.
Tengyun Big HealthTengyun Health is a key emerging industry group and brand in the big health and life sciences sectors, established by Century Golden Resources Investment Group to realize its ecosystem for happiness and health. Aligned with the group’s new industrial strategy of “Grand Consumption, Grand Health, and New Technology,” it also serves as an innovative practice platform for building an open industrial structure in the new era. Dedicated to constructing an all-scenario community health service operation platform that integrates medical care, nursing, rehabilitation, and elderly care, Tengyun Health is developing industrial platforms for smart elderly care, innovative medical devices, and industry-city integration, alongside support platforms for industrial investment, discipline construction, and public welfare initiatives. Through its investment platform, Tengyun Health has collaborated with nearly 20 professional investment institutions and participated in the direct or indirect investment and incubation of over 200 innovative enterprises in healthcare and life sciences.